FDA Panel to Weigh Safety of Peptide Injections Backed by Kennedy and Wellness Influencers

The Food and Drug Administration convenes a two-day advisory meeting beginning Thursday to examine seven peptides that have surged in popularity among wellness communities but lack substantial scientific validation for their safety or efficacy. Health Secretary Robert F. Kennedy Jr., who has publicly declared himself a “big fan” of peptides, is backing the review and has pledged to dismantle regulatory barriers imposed during the Biden administration.

Prominent supporters of peptide accessibility include podcaster Joe Rogan and wellness entrepreneurs such as Gary Brecka, who markets peptide products online and aligns with Kennedy’s “Make America Healthy Again” initiative. Social media platforms overflow with anecdotal claims that these substances enhance muscle development, accelerate injury recovery and produce anti-aging effects.

FDA career scientists have signaled strong skepticism about the compounds, indicating insufficient data exists to justify broader availability through compounding pharmacies—facilities that prepare customized medications unavailable from conventional pharmaceutical manufacturers. Medical and scientific organizations have similarly expressed reservations ahead of the meeting, with Rita Jew, president of the Institute for Safe Medication Practices, calling the situation “really alarming” given the minimal clinical evidence supporting injection of these substances.

The 20-member advisory panel includes at least seven doctors and pharmacists with financial interests in the peptide industry, including operators of wellness clinics selling peptides and online consulting services promoting them. The FDA recently added several additional panelists without industry connections to address prior criticism about conflicts of interest on Kennedy-appointed expert groups.

Peptides function as amino acid chains that form protein components and stimulate hormones regulating growth, metabolism and cellular repair. Pharmaceutical companies have commercialized several peptides as prescription medications, including established therapies for diabetes and weight management.

Advocates seek FDA approval to add seven peptides to the agency’s compounding list for conditions including ulcerative colitis, migraines and opioid dependency. The FDA previously warned the public about risks associated with peptides like BPC-157 and TB-500, both scheduled for Thursday’s review, which are marketed for injury recovery and inflammation reduction but classified as prohibited doping agents internationally.

In a pre-meeting scientific assessment, FDA staff reiterated existing concerns about inadequate safety data, effectiveness documentation and potential hazards from contamination, allergic responses and manufacturing inconsistencies. The agency identified most available evidence from animal studies rather than human trials and recommended against compounding approval for all seven peptides under consideration.

The FDA received more than 1,900 public comments before the meeting, with physicians and patients describing positive personal experiences with peptides. The American Academy of Peptide Medicine contends that regulated pharmacy access provides a safer alternative to uncontrolled market sources for individuals already using these substances.

Following the two-day discussion, the FDA will evaluate advisory votes, testimony and public input to determine whether to expand peptide availability. Policy analysts suggest the agency may issue interim guidance reassuring compounding pharmacies they will not face enforcement action, though formally amending FDA regulations typically requires several months to years. FDA specialist Nathan Beaver suggested the process will likely conclude with outcomes favoring Kennedy’s policy objectives.